Bradley J Monk, Takafumi Toita, Xiaohua Wu, Juan C Vázquez Limón, Rafal Tarnawski, Masaki Mandai, Ronnie Shapira-Frommer, Umesh Mahantshetty, Maria Del Pilar Estevez-Diz, Qi Zhou, Sewanti Limaye, Francisco J Ramirez Godinez, Christina Oppermann Kussler, Szilvia Varga, Natalia Valdiviezo, Daisuke Aoki, Manuel Leiva, Jung-Yun Lee, Raymond Sulay, Yulia Kreynina, Wen-Fang Cheng, Felipe Rey, Yi Rong, Guihao Ke, Sophie Wildsmith, Andrew Lloyd, Hannah Dry, Ana Tablante Nunes, Jyoti Mayadev
BACKGROUND: Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent cervical cancer. We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. METHODS: The CALLA randomised, double-blind, phase 3 trial included 105 hospitals across 15 countries...
December 2023: Lancet Oncology